Yahoo Finance7d
HIV Drugs Market Outlook: Future Trends Indicate a US$ 47.5 Billion Industry by 2034 with a Shift Toward Single-dose Regimens | Report by TMR
The HIV drugs industry consists of antiretroviral therapies (ART) designed to manage HIV infection, suppress viral load, and improve patient survival rates. With the introduction of once-daily ...
Investor's Business Daily on MSN6d
Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding
Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...
Medscape8d
Two-Drug HIV Regimen Matches Standard of Care Therapy in Absence of Drug Resistance Testing
Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.